Bristol-Myers consumer health 7% first quarter growth led by worldwide analgesic sales.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS OTC, NUTRITIONAL SALES INCREASE IN FIRST QUARTER by 7% and 12%, respectively, compared to worldwide sales for the same period in 1996, the company reported April 22. Growth in the nonprescription drugs arena was due in part to increased volume of worldwide analgesic sales, including Efferalgan effervescent acetaminophen (up 17% to $47 mil.), Dafalgan acetaminophen and Aspirin UPSA effervescent aspirin, Bristol-Myers Squibb said. The products, part of BMS' 1994 acquisition of the French manufacturer UPSA, have grown steadily under Bristol-Myers ("The Tan Sheet" Sept. 26 1994, p.15).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning